1 completed, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Spero Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease Placebo, SPR720 500 mg, SPR720 1000 mg - Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) | Phase 2 | Completed | Spero Therapeutics | 25 | 2022-12-14 | 2025-10-09 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease SPR720, Placebo, Open-label Standard of Care - Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease | Phase 2 | Terminated | Spero Therapeutics | 2 | 2020-12-03 | 2022-02-28 |
Mycobacterium avium-intracellulare Infection (2) · Lung Diseases (1)
United States (2)
David Melnick, MD (1) · Xilla Ussrey, MD (1)